Improvement in the psoriasis symptom inventory in moderate-to-severe psoriasis patients on etanercept or adalimumab

被引：0
|
作者：
Patel, Mira [1 ]
Martin, Mona [2 ]
Ortmeier, Brian [3 ]
Kricorian, Greg [3 ]
Wade, Sally [4 ]
Stolshek, Bradley [3 ]
机构：
[1] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
[2] Hlth Res Associates, Mountlake Terrace, WA USA
[3] Amgen Inc, Thousand Oaks, CA USA
[4] Wade Outcomes Res & Consulting, Salt Lake City, UT USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2018年 / 79卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
6905
引用
收藏
页码：AB163 / AB163
页数：1
相关论文
共 50 条
  • [1] Reliability and validity of the psoriasis symptom inventory in patients with moderate-to-severe psoriasis
    Revicki, Dennis A.
    Jin, Ying
    Wilson, Hilary D.
    Chau, Dina
    Viswanathan, Hema N.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2014, 25 (01) : 8 - 14
  • [2] Reliability and validity of the psoriasis symptom inventory in patients with moderate to severe psoriasis
    Revicki, Dennis
    Jin, Ying
    Chau, Dina
    Viswanathan, Hema
    [J]. QUALITY OF LIFE RESEARCH, 2012, 21 : 113 - 113
  • [3] Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
    Griffiths, Christopher E. M.
    Strober, Bruce E.
    van de Kerkhof, Peter
    Ho, Vincent
    Fidelus-Gort, Roseanne
    Yeilding, Newman
    Guzzo, Cynthia
    Xia, Yichuan
    Zhou, Bei
    Li, Shu
    Dooley, Lisa T.
    Goldstein, Neil H.
    Menter, Alan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (02): : 118 - 128
  • [4] Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept
    Griffiths, C. E. M.
    Sterry, W.
    Brock, F.
    Dilleen, M.
    Stefanidis, D.
    Germain, J. M.
    Mallbris, L.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (01) : 230 - 238
  • [5] Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis
    Ferrandiz, C.
    Garcia, A.
    Blasco, A. J.
    Lazaro, P.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 (06) : 768 - 777
  • [6] Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis
    Luger, T. A.
    Barker, J.
    Lambert, J.
    Yang, S.
    Robertson, D.
    Foehl, J.
    Molta, C. T.
    Boggs, R.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (08) : 896 - 904
  • [7] The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients
    Young, Melodie S.
    Horn, Elizabeth J.
    Cather, Jennifer C.
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (01) : 9 - 13
  • [8] Patient choice of dosing frequency among moderate-to-severe plaque psoriasis patients with adalimumab, etanercept, and/or ustekinumab experience
    Carter, Chureen
    Farahi, Kamyar
    Johnson, Michael P.
    Olson, William
    Zhang, Mingliang
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB262 - AB262
  • [9] Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept
    Wang, Ting-Shun
    Tsai, Tsen-Fang
    [J]. DERMATOLOGICA SINICA, 2013, 31 (01) : 11 - 18
  • [10] Joint pain improvement in patients on etanercept therapy for moderate to severe psoriasis
    Tyring, Stephen
    Kricorian, Gregory
    Gordon, Kenneth
    Klekotka, Paul
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB158 - AB158
12345